<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Bristol Myers Squibb’s stock has significantly underperformed the market in recent months due to expiring patents. The market seems to be ignoring the excellent pipeline progress that has occurred as part of the company’s acquisitions of Celgene and MyoKardia.
...read full article on Seeking Alpha
